Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder and is characterized by motor impairment and cognitive and psychiatric symptoms. 
Summary
Huntington's disease (HD) is a fatal neurodegenerative condition, due to a mutation in the IT15 gene encoding for huntingtin. Currently, disease-modifying therapy is not available for HD, and only symptomatic drugs are administered for the management of symptoms. In the last few years, preclinical and clinical studies have indicated that pharmacological strategies aimed at inhibiting cyclic nucleotide phosphodiesterase (PDEs) may develop into a novel therapeutic approach in neurodegenerative disorders. PDEs are a family of enzymes that hydrolyze cyclic nucleotides into monophosphate isoforms. Cyclic nucleotides are second messengers that transduce the signal of hormones and neurotransmitters in many physiological processes, such as protein kinase cascades and synaptic transmission. An alteration in their balance results in the dysregulation of different biological mechanisms (transcriptional dysregulation, immune cell activation, inflammatory mechanisms, and regeneration) that are involved in neurological diseases. In this review, we discuss the action of phosphodiesterase inhibitors and their role as therapeutic agents in HD.
K E Y W O R D S
cyclic nucleotides, Huntington's disease, neuroprotection, PDE inhibitors, phosphodiesterase (PDEs) when mutated. 20, 21 Several studies have shown a downregulation of BDNF levels in cellular and animal models, 19, [21] [22] [23] as well as in postmortem brain of HD patients. 21, 24 Thus, strategies aimed at increasing CREB transcription-and, consequently, the expression of BDNF-have neuroprotective effects in HD animals. [25] [26] [27] CREB activation is mediated by a cAMPdependent protein kinase (PKA). The balance of intracellular cAMP/ cGMP levels, thus, represents an important aspect in the regulation of neuronal processes.
In light of this, PDEs and their inhibitors can play an important role in a therapeutic scenario for HD. In fact, PDEs are enzymes that catabolize cAMP and/or cGMP in the cell. Thus, their inhibition could be beneficial in the neuronal degeneration in the central nervous system (CNS).
In this review, we will discuss the inhibition of PDEs and its neuroprotective action in HD by upregulation of the cyclic nucleotide signaling. Cyclic nucleotides are second messengers in the signal transduction process and synaptic transmission in dopaminergic, noradrenergic and glutamatergic systems in neurons. [30] [31] [32] [33] cAMP and cGMP derives, respectively, from ATP and GTP by the reaction of adenylyl (AC) and guanylyl cyclase (GC). In particular, the cellular mechanism involved is the following: the binding of hormones, neurotransmitters, chemokines, autocrine, and paracrine receptor factors to GPCR receptors (G protein-coupled receptors) activates the heterotrimeric G proteins, consisting of the three subunits (alpha, beta and gamma). 34, 35 In fact, the trans-membrane adenylated cyclic (tAC), activated by the stimulatory G protein (Gs) and inhibited by the inhibitory G protein (Gi), produces 3′,5′-cyclic adenosine monophosphate (cAMP) from ATP; however, it is also synthesized in the brain by soluble adenylate cyclase (AC), whose production is stimulated by bicarbonate (HCO 3 ) and calcium in neuronal cells and in glia. At this point, cyclic AMP stimulates the protein kinase A, the exchange factors directly activated by cAMP 1 (EPAC1 and EPAC2), and/or the cyclic nucleotides gated channels (CNGs). In the case of the production of 3′,5′-cyclic guanosine monophosphate (cGMP), however, nitrogen monoxide (NO) activates soluble GC (sGC), whereas particulate guanylyl cyclase (pGC) is activated through binding of natriuretic peptides (NPs) to coupled receptors. The cGMP, produced from the GTP, will in turn activate the protein kinase G and CNGs.
| MOLECUL AR MECHANIS M OF PDE S FUN C TION
Formation of both cAMP and cGMP involves activation of CREB by phosphorylation, generating the transcription of several genes.
As previously mentioned, both cAMP and cGMP are neutralized through the hydrolysis performed by phosphodiesterases. 
| PHOS PHOD IE S TER A S E S IN D O PA M I N ERG I C PATHWAYS
As mentioned previously, the dopaminergic system is altered in neurodegenerative and neuropsychiatric diseases, and among these also in Huntington's disease. These diseases have in common the cortico-striato-thalamic systems, which work in a synergistic and complex way, [55] [56] [57] [58] [59] and in which the alteration of the balance involves the appearance of motor, cognitive, and behavioral dysfunctions typical of these disorders. Dopamine appears to be the modulator of these circuits both in the frontal cortex and in the striatum, regions in which dopamine receptors are strongly distributed. 57, 60, 61 In fact, as it is well known, some of these diseases, such as PD, use dopaminergic therapy to fight its symptoms, although it subsequently involves various side effects. Dopamine, originating from the pars compacta of the substantia nigra or from the VTA, is bound to the D1 receptors on the MSNs neurons of the direct pathway activating the stimulatory (Golf, Gs) and stimulating the production of cAMP, or to the D2 receptors of the indirect pathway that bind to the inhibitory G protein (Gi) that inhibits the production of cAMP. 57, [62] [63] [64] [65] [66] This information therefore establishes the central role played by dopamine in the regulation of psychomotor mechanisms. As mentioned above, the action of dopamine occurs through the signal transduction mechanism operated by the cAMP/PKA system and is also controlled by phosphodiesterases. 67 In the striatum, the regulation of cAMP and cGMP turnover plays a fundamental role because of their inhibitory and excitatory effects of the nigro-striated-pallid circuits, mentioned before, in neurons. In the striatum are expressed many phosphodiesterase isoforms, which have various localizations and functions influencing synaptic plasticity and excitability of the membrane. movement. On the contrary, in the late stages of the pathology, there is a reduction in dopamine neurotransmission with the consequent appearance of hypokinesia. Various studies have also observed the loss of dopaminergic innervation and a reduction in TH + neurons in the striatum of postmortem brains of HD patients. 90 These observations were confirmed in PET studies conducted both on patients with overt disease and on patients with the modified gene but who still had not shown the typical symptoms of the disease. 91, 92 These data have been confirmed in animal models. [93] [94] [95] Furthermore, a reduction in dopamine D1 and D2 receptor levels was also evidenced. 96 
| PDE S IN H UNTING TON ' S D IS E A S E
In the following section, we examine the different PDEs that play a role in HD pathology, with regard to their tissue distribution, and to the inhibitors that have been tested so far in clinical and preclinical trials in HD ( Table 1) .
As mentioned above, PDEs and their relative inhibitors could be considered a new therapeutic strategy in HD. In fact, various studies showed beneficial, neuroprotective effects of PDEs inhibitors in animal models of HD improving motor and cognitive problems but also increasing the expression of species such as pCREB and BDNF, altered, as mentioned, in Huntington's disease [97] [98] [99] [100] (Figure 1 ).
| PDE 1
Phosphodiesterase 1 (PDE1) hydrolyzes both cAMP and cGMP. It has three isoforms (PDE1A, PDE1B, PDE1C), two of which (PDE1A and PDE1B) are expressed in striatum, as well as in cortex and hippocampus as PDE1C. Particularly, PDE1B is ubiquitously distributed in spiny projection neurons and colocalizes with D1 receptors, 101 suggesting a possible involvement of this isoform in striatal neurodegeneration and dopaminergic signaling. 102, 103 PDE1 is not localized only in cytoplasm, but, for example, PDE1A is expressed in nucleus, which has a regulation activity of gene transcription. 104 For its high expression in striatum and frontal cortex and its colocalization with D1 receptor, PDE1B could be considered a good target for phosphodiesterase inhibitors in disorders characterized by cognitive complications (schizophrenia) and motor dysfunction. Therefore, PDE1 inhibition was studied in Parkinson's disease. In fact, vinpocetine is a PDE1 inhibitor characterized by the capacity to reduce neuronal inflammation and the expression of TNF-α and IL-1β. 105 In many studies, this compound has shown neuroprotective properties: regulate oxidative stress and enhance cognition in behavioral test and memory both in animal models and patients. [106] [107] [108] Interestingly, PDE1A2 isoform was found to be preferentially distributed in cholinergic interneurons, 103 suggesting a role in the survival of striatal interneurons in HD.
With the aim of shedding light on the role of PDEs in HD, vinpocetine treatment was shown to ameliorate impaired cognition and motor coordination in a 3-nitroproprionic acid-induced HD rat model, by reducing oxidative species, inflammation, and mitochondrial dysfunction. 109 Recently, a new molecule capable of inhibiting PDE1 has been discovered. It has been tested in PHASE 1 of a clinical trial and has shown positive effects not only in Alzheimer's disease and schizophrenia, but also in movement disorders. 110 Thus, inhibition of PDE1 could be seen as a potential drug target in HD treatment, although more precise studies are necessary in both clinical and preclinical research in HD.
| PDE 4
The best described PDEs are the PDE4 family, composed by four different enzymes (PDE4A, PDE4B, PDE4C, and PDE4D). With the exception of PDE4C, the other isoforms are ubiquitous in the central nervous systems, and their distribution is particularly high in the striatum, cortex, and hippocampus.
111
PDE4 has distinct functions in the dopaminergic system because of its different distribution to the various striatal neuronal subtypes.
Moreover, indirect pathway presents a higher expression of PDE4B than direct pathway. Thus inhibition of PDE4 regulates and ameliorates cAMP/PKA signaling in the indirect pathway neurons, and at the same time, upregulating TH activation and dopamine formation.
112
In fact, regulating cAMP balance PDE4 is essential in the PKA/ CREB/BDNF pathway, as demonstrated by the CREB-upregulating effects of PDE inhibition in depressive behavior. 113, 114 As mentioned earlier, CREB represents an important transcription factor, as it is needed for adult neuronal survival and for mediating nuclear calcium-regulated gene transcription. CREB is activated by cAMP-dependent protein kinase (PKA) by the phosphorylation of its Ser 133 . Consequently, the activated form pCREB binds to CREs elements (cyclic AMP response elements) on the promoter region of DNA and promotes the transcription of various genes involved in memory and neuronal plasticity, such as BDNF. [115] [116] [117] Our group previously confirmed the abnormalities in CREB transcription in the quinolinic-induced rat model of HD, describing a differential modulation of pCREB in the striatal neuronal population. 46 Particularly, a decreased expression in the neurons most vulnerable to HD (medium spiny neurons, parvalbumin and carletinin positive interneuron) was observed. On the other hand, cholinergic interneurons conserve adequate pCREB expression, and probably this event confers their neuroprotection. 46 Interestingly, however, PDE4 in HD was described to be decreased in R6/2 mice, suggesting a compensatory mechanism due to a concurrent decrease in CREB activation, as seen above. 118 The first generation of PDE4 inhibitor is rolipram. Previous studies of our group showed that this PDE4 inhibitor is able to increase the levels of pCREB (the activated form of CREB) in the medium spiny neurons, with neuroprotective effects both in HD rat model induced by quinolinic acid, and in R6/2 transgenic HD mice. These effects were demonstrated by the reduction of intranuclear formation of mutant huntingtin inclusions, sparing of striatal neurons, decrease in microglial activation, the delay of onset, and decrease in severity of neurological impairment and movement defects. [119] [120] [121] In spite of the promising results obtained in animal models, these inhibitors have not proved to be successful in human clinical trials:
rolipram have various side effects, such as nausea and emesis, 122 and in multiple sclerosis MRI showed an increase in brain inflammatory processes measured by brain lesions. 123 Thus, recently, the new purpose of the research will be to study new inhibitors that do not have the aforementioned side effects. 124, 125 The last clinical study in HD is represented by the PDE4 inhibitor GSK356278 (GlaxoSmithKline) that has shown good tolerability in patients although the improvement in motor and cognitive symptoms is not clear. 
| PDE 5
PDE 5 is specific to cGMP and is abundant in striatum, cortex, and hippocampus. 126 Inhibition of these phosphodiesterases showed positive effects in rats as far as it concerns memory amelioration, 127,128 synaptic plasticity, 129 and depressive symptoms. This confirms the importance of cGMP pathway in HD pathology, suggesting PDE5 inhibitors as a possible therapeutic strategy in HD.
| PDE 10
Phosphodiesterase 10 is an enzyme with a double specificity for cAMP and cGMP, characterized by its high level of expression in striatum, nucleus accumbens, and olfactory tubercle. PDE10A is also distributed in hippocampus, thalamus, cerebellum, and spinal cord. [133] [134] [135] [136] PDE10 expression in the caudate portion of the basal ganglia suggests a role of this enzyme in striatonigral and striatopallidal pathways. 137 Xie et al 137 described PDE10A localization only in medium spiny neurons, whereas it was not expressed in interneurons. Because of such peculiar expression in medium spiny neurons (MSNs), PDE10A involvement was studied in dopamine signaling.
Many studies showed that inhibition of PDE10A involves the activation of D1-direct and D2-indirect pathway. [138] [139] [140] [141] 
151
The effects of PDE10A inhibition are still under investigation. A Phase II clinical trial has just been concluded: PF-0254920 drug was used to taste safety and tolerability in HD patients. Unfortunately, with the data available so far, the drug does not ameliorate movement and/or behavioral problems. 152 
| CON CLUS IONS
This review highlighted the important role that phosphodiesterases plays in many cellular processes under physiological and/or pathological conditions. Therefore, we have described in more detail the phosphodiesterases expressed in the striatum and related brain regions, the main target of the Huntington pathology, and more involved in the regulation of the dopaminergic system, universally recognized as altered in the aforesaid pathology. All the studies presented here suggest the use of PDE inhibitors in HD, in order to potentiate cAMP signaling in the striatum.
As mentioned elsewhere, in recent years the therapeutic role of phosphodiesterase regulation has emerged through their inhibition. 
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